Seeking Alpha

Oncolytics Biotech (ONCY) -13.4% premarket after saying it will expand enrollment in its Phase...

Oncolytics Biotech (ONCY) -13.4% premarket after saying it will expand enrollment in its Phase III study of Reolysin, a possible treatment for head and neck cancers, after observing different responses in two different groups of patients.
Comments (1)
  • billyboys2
    , contributor
    Comment (1) | Send Message
     
    this could be positive
    14 Sep 2012, 10:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|